Recent studies have found that in GBM, triple-negative breast cancer, and pancreatic tumors, ferroptosis inhibition combined with anti-PD-1 can improve the efficacy of single immunotherapy, suggesting a synergistic effect of ferroptosis inhibition and anti-PD-1 (147–149). The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.